NEW YORK, August 18, 2016 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com takes a closer look at these four equities: Illumina Inc. (NASDAQ: ILMN),
XOMA Corp. (NASDAQ: XOMA), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and VIVUS Inc. (NASDAQ: VVUS). According to Morgan
Stanley's Adam Parker, U.S. Biotech stocks are now trading at equal or lower valuations as
U.S. and European pharmaceutical companies on price-to-forward earnings and at a slight discount on price-to-operating cash flow.
Learn more about these stocks by downloading their comprehensive and free reports at:
http://stock-callers.com/registration
Illumina
On Wednesday, shares in San Diego, California headquartered Illumina Inc. recorded a trading
volume of 922,623 shares. The stock ended the session 0.29% lower at $169.15. The Company's shares
have gained 13.77% in the last one month and 20.62% in the previous three months. The stock is trading 12.64% above its 50-day
moving average and 7.63% above its 200-day moving average. Moreover, shares of Illumina, which provides sequencing and
array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 63.88.
On July 27th, 2016, research firm Mizuho reiterated its 'Neutral' rating on the
Company's stock with an increase of the target price from $138 a share to $148 a share.
On August 8th, 2016, Personal Genome Diagnostics Inc., a leading provider of advanced
cancer genome testing products and services, announced an agreement with Illumina to develop two in-vitro diagnostic test kits
for use on Illumina's sequencing instruments, including kits for the detection and characterization of tumor DNA using both
tissue and plasma samples. ILMN complete research report is just a click away and free at:
http://stock-callers.com/registration/?symbol=ILMN
XOMA Corp.
Berkeley, California headquartered XOMA Corp.'s stock closed the day 1.55% lower at
$0.60 and with a total volume of 487,997 shares traded. The Company's shares have advanced 19.12%
in the past one month. The stock is trading 2.50% above its 50-day moving average. Additionally, shares of XOMA, which discovers,
develops, and commercializes antibody-based therapeutics in the US, Europe, and the Asia Pacific, have an RSI of 49.65.
On August 4th, 2016, XOMA recorded total revenues of $0.4
million for the three months ended June 30th, 2016, compared to $2.5 million during the corresponding period of 2015. The decrease in Q2 2016 revenues was due primarily to
decreased revenues from the National Institute of Allergy and Infectious Diseases and Servier. Research and development expenses
for Q2 2016 were $13.7 million, compared with $19.7 million in the
corresponding 2015 period. The complimentary report on XOMA can be downloaded at:
http://stock-callers.com/registration/?symbol=XOMA
Lexicon Pharma
Shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. recorded a trading
volume of 553,247 shares. The stock ended yesterday's trading session 0.77% lower at $15.53. The
Company's shares have advanced 6.08% in the past one month, 23.75% in the previous three months, and 16.68% on an YTD basis. The
stock is trading above its 50-day and 200-day moving averages by 3.77% and 21.36%, respectively. Furthermore, shares of Lexicon
Pharmaceuticals, which focuses on the discovery and development of pharmaceutical products for the treatment of human diseases,
have an RSI of 49.24.
On August 4th, 2016, Lexicon Pharmaceuticals reported that revenues for the three
months ended June 30th, 2016 increased to $20.1 million
from $0.4 million for the corresponding period in 2015, primarily due to revenues recognized from
the collaboration and license agreement with Sanofi. The company noted that net loss for the three months ended June 30th, 2016 was $38.1 million, or $0.37 per share, compared to a net loss of $28.1 million, or $0.27 per share, in the corresponding period in 2015.
On August 5th, 2016, research firm Wedbush reiterated its 'Outperform' rating on the
Company's stock with an increase of the target price from $30 a share to $31 a share. Sign up for your complimentary research report on LXRX at:
http://stock-callers.com/registration/?symbol=LXRX
VIVUS
Mountain View, California headquartered VIVUS Inc.'s stock finished the session 0.94% lower
at $1.05 with a total volume of 238,531 shares traded. The Company's shares have advanced 2.94%
since the start of this year. The stock is trading below its 50-day moving averages by 6.78%. Additionally, shares of VIVUS,
which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of
44.21.
On July 27th, 2016, VIVUS announced that it has filed a lawsuit against Hetero
USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero. The lawsuit was filed in
response to an Abbreviated New Drug Application, filed by Hetero. In its application, Hetero seeks to market and sell generic
versions of the currently approved doses of STENDRA® (avanafil) tablets prior to the expiration of U.S. Patents 6,656,935 and
7,501,409, which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Get
free access to your research report on VVUS at:
http://stock-callers.com/registration/?symbol=VVUS
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA